Inhaled Delivery of Vidaza for Targeted Epigenetic Lung Cancer Therapy
吸入 Vidaza 用于靶向表观遗传肺癌治疗
基本信息
- 批准号:10208793
- 负责人:
- 金额:$ 47.58万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-07-01 至 2023-06-30
- 项目状态:已结题
- 来源:
- 关键词:AdjuvantAdjuvant TherapyAerosolsAffectAmino AcidsApoptosisAzacitidineCancer EtiologyCancer ModelCatabolismCell LineCell ProliferationCell SurvivalChromatin Remodeling FactorChronicCombined Modality TherapyCoupledCytidineCytidine DeaminaseCytosineDeacetylationDeaminationDiagnosisDiffusionDiseaseDoseDrug KineticsEZH2 geneEpigenetic ProcessEvolutionFormulationFunctional disorderFutureGene SilencingGenesGenetic TranscriptionGoalsGravitationGrowthHalf-LifeHepaticHeterogeneityHistologyHistone DeacetylaseHistone Deacetylase InhibitorHistonesHumanHydrolysisHypermethylationIn VitroInhalationLungLung NeoplasmsMalignant NeoplasmsMalignant neoplasm of lungMethylationModelingModificationMolecularNeoplasm MetastasisNon-Small-Cell Lung CarcinomaNude RatsOralParticle SizePathogenesisPathway interactionsPatientsPerformancePeripheralPharmaceutical PreparationsPharmacologyPhasePhase I/II Clinical TrialPhase II Clinical TrialsPowder dose formProgression-Free SurvivalsPromoter RegionsRattusRefractoryRelapseRouteScheduleSecondary PreventionSedimentation processSquamous CellTestingThe Cancer Genome AtlasTranslatingTumor BurdenTumor Suppressor GenesTumor-DerivedVidazaWorkXenograft procedureabsorptionaerosolizedaqueousbasecancer cellcancer clinical trialcancer therapycell growthchemotherapycomparative efficacydemethylationepigenetic therapyepigenomegene panelhistone methylationhistone methyltransferaseimprovedin vivoinhibitor/antagonistinnovationnovelpartial responsephase II trialphase III trialpromoterpublic health relevanceresponsesmall molecule inhibitorsubcutaneoussystemic toxicitytargeted treatmenttreatment responsetumortumor growthtumor heterogeneityvirtual
项目摘要
DESCRIPTION: The evolution of novel targeted- and chemo-therapies for LC has achieved modest improvement in median survival for advanced LC, but they offer no clear path to treatments that could make this a chronic, rather than fatal disease. Furthermore, for the majority of the more than 220,000 new lung cancer cases diagnosed annually in the US for which most targeted therapy is not an option, durable responses with chemotherapy are uncommon and median survival after relapse is only 6.5 months. This presents a daunting challenge to develop a different "outside of the box" approach with low systemic toxicity that in turn will allow chronic dosing to achieve and sustain therapeutic responses. The Cancer Genome Atlas has interrogated over 600 non-small cell lung cancers (NSCLCs) and revealed that virtually all tumors contain hundreds of genes that have densely cytosine methylated promoter regions leading to reduced transcription. Epigenetic therapy through its ability to awaken these genes offers a strategy that could ultimately produce durable and sustained tumor regression. A Phase II trial combining non-cytotoxic doses of the demethylating agent Vidaza (5- azacytidine) with the histone deacetylase (HDAC) inhibitor entinostat (MS275) showed promising results in patients with refractory, advanced NSCLC. The required continuous daily subcutaneous dosing schedule may constrain the expansion of epigenetic therapy in Phase III trials or in adjuvant therapy, while oral formulations are problematic due to hydrolysis; both dosing routes are subjected to catabolism by cytidine deaminase that greatly reduces Vidaza half-life. These barriers to expanding use and improving the response to epigenetic therapy could be mitigated by aerosolized administration that would deliver Vidaza directly to the lungs. The absorption of the aerosol into the pulmonary vasculature also avoids hepatic first pass, thus eliminating initial inactivation by cytidine deamination, while providing systemic dose to treat occult metastases. The orthotopic lung cancer model we developed in which xenografts of human lung cancer-derived cell lines are engrafted throughout the lungs of the nude rat allows testing of combination therapies and different routes of administration. Our first studies demonstrated that systemic delivery of Vidaza and entinostat at doses and schedule similar to the Phase II clinical trial were synergistic in suppressing tumor growth by 60% and induced reprogramming of the epigenome as detected by gene demethylation and re-expression. Recent studies now show that an aqueous formulation of Vidaza administered as an aerosol can effectively reduce lung tumor burden and induce common global demethylation of 300 genes at one-third the comparable effective systemic dose. The major goals of this application are to develop an optimal aerosol formulation of Vidaza, and to develop dosing strategies in combination with entinostat and inhibitors of histone methylation that maximally affect tumor burden and reprogramming of the epigenome in NSCLC using our orthotopic model. The culmination of this work will enable future innovative Phase I/II lung cancer clinical trials.
产品说明:LC的新型靶向和化学疗法的发展已经在晚期LC的中位生存期方面取得了适度的改善,但它们没有提供明确的治疗途径,可以使其成为慢性而不是致命的疾病。此外,对于美国每年诊断的超过220,000例新肺癌病例中的大多数,大多数靶向治疗不是一种选择,化疗的持久反应是罕见的,复发后的中位生存期仅为6.5个月。这提出了一个艰巨的挑战,以开发一个不同的“盒子外”的方法,具有低全身毒性,这反过来将允许长期给药,以实现和维持治疗反应。癌症基因组图谱已经询问了600多个非小细胞肺癌(NSCLC),并发现几乎所有的肿瘤都含有数百个基因,这些基因具有密集的胞嘧啶甲基化启动子区域,导致转录减少。表观遗传疗法通过其唤醒这些基因的能力提供了一种策略,最终可以产生持久和持续的肿瘤消退。一项II期试验将非细胞毒性剂量的去甲基化剂维达扎(5-氮杂胞苷)与组蛋白去乙酰化酶(HDAC)抑制剂恩替司他(MS 275)相结合,在难治性晚期NSCLC患者中显示出有希望的结果。所需的连续每日皮下给药方案可能会限制表观遗传治疗在III期试验或辅助治疗中的扩展,而口服制剂由于水解而存在问题;两种给药途径都受到胞苷脱氨酶的催化作用,大大缩短了维达扎的半衰期。这些扩大使用和改善对表观遗传疗法的反应的障碍可以通过雾化给药来缓解,雾化给药将Vidaza直接输送到肺部。气雾剂吸收到肺血管中也避免了肝脏首过,从而消除了胞苷脱氨基作用的初始灭活,同时提供全身剂量以治疗隐匿性转移。我们开发的原位肺癌模型,其中人肺癌衍生细胞系的异种移植物被移植到裸大鼠的整个肺中,允许测试组合疗法和不同的给药途径。我们的第一项研究表明,以类似于II期临床试验的剂量和时间表全身递送维达扎和恩替司他在抑制肿瘤生长60%方面具有协同作用,并诱导表观基因组的重编程,如通过基因去甲基化和重表达所检测到的。最近的研究表明,以气雾剂形式给药的Vidaza水性制剂可以有效降低肺肿瘤负荷,并以相当于有效全身剂量的三分之一诱导300个基因的常见整体去甲基化。本申请的主要目标是开发Vidaza的最佳气雾剂制剂,并开发与恩替司他和组蛋白甲基化抑制剂组合的给药策略,其使用我们的原位模型最大限度地影响NSCLC中的肿瘤负荷和表观基因组的重编程。这项工作的成果将使未来的创新I/II期肺癌临床试验成为可能。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Steven A Belinsky其他文献
Early menopause and hormone therapy as determinants for lung health outcomes: a secondary analysis using the PLCO trial.
早期绝经和激素治疗作为肺部健康结果的决定因素:使用 PLCO 试验的二次分析。
- DOI:
- 发表时间:
2024 - 期刊:
- 影响因子:10
- 作者:
Xiaochun Gai;Yue Feng;Tessa M Flores;Huining Kang;Hui Yu;Kimberly K Leslie;Yiliang Zhu;Jennifer A Doherty;Yan Guo;Steven A Belinsky;Linda S Cook;Shuguang Leng - 通讯作者:
Shuguang Leng
Steven A Belinsky的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Steven A Belinsky', 18)}}的其他基金
Aerosolized Epigenetic Therapy for Metastatic Lung Cancer
雾化表观遗传疗法治疗转移性肺癌
- 批准号:
10760630 - 财政年份:2023
- 资助金额:
$ 47.58万 - 项目类别:
Assessing Toxicant Properties and Health Effects of Cigarillo and Hookah Tobacco Aerosols in Rats
评估小雪茄和水烟气溶胶对大鼠的毒性特性和健康影响
- 批准号:
10413991 - 财政年份:2020
- 资助金额:
$ 47.58万 - 项目类别:
DNA Repair Capacity Assays for Lung Disease Risk Assessment
用于肺部疾病风险评估的 DNA 修复能力测定
- 批准号:
10470762 - 财政年份:2018
- 资助金额:
$ 47.58万 - 项目类别:
Assessing Toxicant Properties of Cigarillo and Hookah Aerosols in Lung Epithelial and Cardiac Cells Through Aerosol Exposure
通过气溶胶暴露评估小雪茄和水烟气溶胶对肺上皮和心肌细胞的毒性特性
- 批准号:
9788459 - 财政年份:2018
- 资助金额:
$ 47.58万 - 项目类别:
DNA Repair Capacity Assays for Lung Disease Risk Assessment
用于肺部疾病风险评估的 DNA 修复能力测定
- 批准号:
10296957 - 财政年份:2018
- 资助金额:
$ 47.58万 - 项目类别:
DNA Repair Capacity Assays for Lung Disease Risk Assessment
用于肺部疾病风险评估的 DNA 修复能力测定
- 批准号:
9768991 - 财政年份:2018
- 资助金额:
$ 47.58万 - 项目类别:
Assessing Toxicant Properties of Cigarillo and Hookah Aerosols in Lung Epithelial and Cardiac Cells Through Aerosol Exposure
通过气溶胶暴露评估小雪茄和水烟气溶胶对肺上皮和心肌细胞的毒性特性
- 批准号:
9976518 - 财政年份:2018
- 资助金额:
$ 47.58万 - 项目类别:
Deposition Profile and Toxicology of E-Cigarettes in the Oral Epithelium
电子烟在口腔上皮细胞中的沉积概况和毒理学
- 批准号:
9117092 - 财政年份:2016
- 资助金额:
$ 47.58万 - 项目类别:
Inhaled Delivery of Vidaza for Targeted Epigenetic Lung Cancer Therapy
吸入 Vidaza 用于靶向表观遗传肺癌治疗
- 批准号:
10296534 - 财政年份:2016
- 资助金额:
$ 47.58万 - 项目类别:
Histone Methyltransferases as a Target for Lung Cancer Prevention
组蛋白甲基转移酶作为肺癌预防的靶点
- 批准号:
8856526 - 财政年份:2014
- 资助金额:
$ 47.58万 - 项目类别:
相似海外基金
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 47.58万 - 项目类别:
The ESCAPE clinical trial of circulating tumor DNA to guide adjuvant therapy in chemo-resistant triple negative breast cancer
循环肿瘤 DNA 指导化疗耐药三阴性乳腺癌辅助治疗的 ESCAPE 临床试验
- 批准号:
494901 - 财政年份:2023
- 资助金额:
$ 47.58万 - 项目类别:
Operating Grants
A Type I Hybrid Effectiveness-Implementation Trial to Evaluate a Navigation-Based Multilevel Intervention to Decrease Delays Starting Adjuvant Therapy Among Patients with Head and Neck Cancer
一项 I 型混合有效性实施试验,用于评估基于导航的多级干预措施,以减少头颈癌患者开始辅助治疗的延迟
- 批准号:
10714537 - 财政年份:2023
- 资助金额:
$ 47.58万 - 项目类别:
Multi-modal machine learning to guide adjuvant therapy in surgically resectable colorectal cancer
多模式机器学习指导可手术切除结直肠癌的辅助治疗
- 批准号:
10588103 - 财政年份:2023
- 资助金额:
$ 47.58万 - 项目类别:
Efficacy of ethanol adjuvant therapy after resection of malignant soft tissue tumors
恶性软组织肿瘤切除术后乙醇辅助治疗的疗效
- 批准号:
22K09407 - 财政年份:2022
- 资助金额:
$ 47.58万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of immune response cells and development of novel adjuvant therapy for sublingual immunotherapy
免疫应答细胞的鉴定和舌下免疫治疗新型辅助疗法的开发
- 批准号:
21KK0287 - 财政年份:2022
- 资助金额:
$ 47.58万 - 项目类别:
Fund for the Promotion of Joint International Research (Fostering Joint International Research (A))
Pursuing molecular biomarkers to guide adjuvant therapy for HPV+ head and neck cancers after transoral robotic surgery
寻找分子生物标志物来指导经口机器人手术后 HPV 头颈癌的辅助治疗
- 批准号:
10357120 - 财政年份:2022
- 资助金额:
$ 47.58万 - 项目类别:
Biomarker research using two prospective studies on preoperative and postoperative adjuvant therapy for pancreatic cancer
使用两项关于胰腺癌术前和术后辅助治疗的前瞻性研究进行生物标志物研究
- 批准号:
21K08700 - 财政年份:2021
- 资助金额:
$ 47.58万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Personalized Resistant Starch as an Adjuvant Therapy for Pediatric Inflammatory Bowel Disease
个性化抗性淀粉作为小儿炎症性肠病的辅助治疗
- 批准号:
437315 - 财政年份:2020
- 资助金额:
$ 47.58万 - 项目类别:
Studentship Programs
Tailored adjuvant therapy in POLE-mutated and p53-wildtype early stage endometrial cancer (TAPER)
POLE 突变和 p53 野生型早期子宫内膜癌 (TAPER) 的定制辅助治疗
- 批准号:
435603 - 财政年份:2020
- 资助金额:
$ 47.58万 - 项目类别:
Operating Grants